Actinium Pharmaceuticals, Inc. ATNM 深 滬
等待開盤 12-16 09:30:00 美东时间
1.59
+0.080
+5.30%
華盛通- 最 高1.69
- 今 開1.52
- 成交量 31.24万股
- 最 低 1.52
- 昨 收 1.51
- 總市值 4960.15万
- 52周最高 2.41
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 1.0292
- 委 比 20.00%
- 總股本 3119.59万
- 歷史最高 450.00
- 量 比 1.45
- 振 幅 11.26%
- 歷史最低 1.0292
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Actinium Pharma Advances Solid-Tumor Program With Phase 1 Clinical Trial In South Africa Targeting B7-H3
Actinium Pharmaceuticals (NYSE:ATNM), a company developing targeted alpha radiotherapies, is advancing its solid-tumor program with a Phase 1 clinical trial in South Africa targeting B7-H3. This study represents one of
12-09 03:48
Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In HR+, HER2+ And Triple-Negative Breast Cancer At SABCS 2025
Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a novel
12-01 21:49
Actinium To Present New Breast Cancer Data On Its ATNM-400 Radiotherapy At San Antonio Symposium
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for its lead antibody
11-04 20:34
Actinium Pharmaceuticals Presents New Preclinical Data For ATNM-400 Antibody Radioconjugate At 32nd Annual Prostate Cancer Foundation Scientific Retreat In Carlsbad, California
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today highlighted new preclinical data for ATNM-400, its novel,
10-24 20:31
Actinium Pharmaceuticals Announces That The First-Ever Preclinical Data From Its ATNM-400 Program In Non-Small Cell Lung Cancer Has Been Accepted For Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics Being Held October 22 – 26, 2025
NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from
10-14 00:14
ATN Board Declares Quarterly Dividend
ATN International, Inc. (Nasdaq: ATNI) announced a quarterly dividend of $0.275 per share, payable on October 7, 2025, to stockholders of record as of September 30, 2025. Headquartered in Beverly, Massachusetts, ATNI provides digital infrastructure and communication services in the U.S. and internationally, focusing on rural and remote markets. The company offers advanced wireless and wireline connectivity, high-speed internet, and carrier servic...
09-18 20:00
Advent Technologies and Stralis announce Pioneering Relationship to Advance Hydrogen Electric Flight
Advent Technologies Holdings, Inc. is supplying its proprietary membrane electrode assembly technology to Stralis Aircraft for their hydrogen electric Beechcraft Bonanza aircraft. Advent's HT-PEM technology reduces radiator size, weight, and drag, enabling efficient cooling. Stralis' hydrogen-electric propulsion system is significantly lighter, allowing flights 10 times farther than battery-electric alternatives at a lower cost. This system is ex...
08-18 12:30
ATN Announces Updated Start Time for Second Quarter 2025 Financial Results Conference Call on August 8, 2025
ATN International has announced a change to the start time of its Q2 2025 financial results conference call, which will now begin at 9:00 a.m. ET on Friday, August 8, 2025, one hour earlier than previously scheduled. All other details remain unchanged. The call will be webcast live and a replay will be available shortly after. The Company, headquartered in Beverly, Massachusetts, provides digital infrastructure and communications services to rura...
07-29 19:00
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Actinium Pharma Reports New Preclinical Data From Non-PSMA Targeting Radiotherapy Prostate Cancer Candidate ATNM-400, At SNMMI Annual Meeting
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination- ATNM-400 is
06-23 23:33
